STOCK TITAN

Intra-Cellular Therapies Inc - ITCI STOCK NEWS

Welcome to our dedicated news page for Intra-Cellular Therapies (Ticker: ITCI), a resource for investors and traders seeking the latest updates and insights on Intra-Cellular Therapies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Intra-Cellular Therapies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Intra-Cellular Therapies's position in the market.

Rhea-AI Summary
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced the promotion of Michael Halstead, J.D. to President, overseeing key company functions. Larry Hineline, CFO, will retire after 20+ years of service, initiating a search for a replacement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
management
-
Rhea-AI Summary
Intra-Cellular Therapies, Inc. (ITCI) is set to participate in three upcoming investor conferences to showcase their developments in CNS therapeutics. The company will present at Leerink Partners Global Biopharma Conference, Jefferies Biotech on the Bay Summit, and UBS Virtual CNS Day in March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
conferences
-
Rhea-AI Summary
Intra-Cellular Therapies, Inc. announced that CEO Sharon Mates will present at the 44th Annual TD Cowen Health Care Conference. The presentation will focus on the development and commercialization of therapeutics for CNS disorders. The webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
conferences
Rhea-AI Summary
Intra-Cellular Therapies, Inc. reported strong financial results for 2023 with total revenues of $464.4 million, driven by CAPLYTA net product sales of $462.2 million, an 86% increase from 2022. The company provided a positive outlook for 2024 with expected net product sales of $645 to $675 million. Key clinical highlights include advancements in lumateperone programs for various disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
earnings
-
Rhea-AI Summary
Intra-Cellular Therapies, Inc. will host a conference call and live webcast discussion to provide a corporate update and discuss financial results for the quarter and year ended December 31, 2023. The event will take place on Thursday, February 22, 2024, at 8:30 a.m. Eastern Time. Participants can register for the conference call via a provided link and access the webcast on the Company's website. The focus of the call will be on the development and commercialization of therapeutics for central nervous system disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.42%
Tags
conferences earnings
-
Rhea-AI Summary
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
conferences
Rhea-AI Summary
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) presents positive results of a pre-specified patient population in Study 403 examining the effects of CAPLYTA® (lumateperone) in patients experiencing a major depressive episode with anxious distress and mixed features. The company also presents preclinical data on ITI-1549, their lead product candidate in their non-hallucinogenic psychedelics program in mood disorders and other psychiatric disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
none
-
Rhea-AI Summary
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) to Present at Evercore ISI HealthCONx Conference on November 28, 2023. The biopharmaceutical company will discuss its focus on developing therapeutics for CNS disorders. The live webcast can be accessed on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
conferences
-
Rhea-AI Summary
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) reported Q3 2023 total revenues of $126.2 million, a 75% increase compared to the same period in 2022. CAPLYTA Q3 2023 net product sales were $125.8 million, representing a 75% increase. CAPLYTA total prescriptions increased 71% in Q3 2023. The company raised its 2023 CAPLYTA net product sales guidance to $460-$470 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
earnings
Rhea-AI Summary
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) will participate in two investor conferences: J.P. Morgan Equity Opportunities Forum on Nov 6-7 and UBS Biopharma Conference on Nov 8. A live and archived webcast of the fireside chat at the UBS Biopharma Conference will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.31%
Tags
conferences
Intra-Cellular Therapies Inc

Nasdaq:ITCI

ITCI Rankings

ITCI Stock Data

6.75B
94.59M
2.51%
98.67%
3.82%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About ITCI

intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.